Stellar Biotechnologies produces and markets keyhole limpet hemocyanin (KLH), as well as develops technology related to the culture and production of KLH and KLH subunit formulations in the United States and Europe. The company’s KLH is an immunogenic high-molecular-weight protein, which is used in cancer and therapeutic vaccines for lymphoma, bladder, breast, colon, sarcoma, small cell lung cancer, Alzheimer’s disease, rheumatoid arthritis, lupus, and post-traumatic stress disorder chemical dependencies. For further information, visit the company’s Web site www.stellarbiotechnologies.com

Noble Financial Capital Markets, an equity research driven, full-service, investment banking boutique, is hosting its ninth annual equity conference at The Hard Rock Hotel in Ft. Lauderdale, FL. Attended by institutional investors from across North America, the event features 135 public company executive teams with an emphasis on healthcare, technology, defense, and new-media / entertainment sectors.

Let us hear your thoughts below: